Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy

Xiao-mei Hu; Feng Liu; Chun-mei Zheng; Liu Li; Chi Liu; Shan-shan Zhang; Hai-yan Xiao; Xiao-hong Yang; Hong-zhi Wang; Yong-gang Xu; Nai-ping Hu; Rou Ma

doi:10.1007/s11655-009-0193-x

Your Location：

Home >

Browse articles >

Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy

Updated：2021-08-27

- Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy
- Chinese Journal of Integrative Medicine Vol. 15, Issue 3, Pages: 193-197(2009)
- Affiliations：
  
  Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-009-0193-x
  CLC：
- Published：2009，
  
  Published Online：2 July 2009，
Scan for full text
Hu, Xm., Liu, F., Zheng, Cm. et al. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy., Chin. J. Integr. Med. 15, 193–197 (2009). https://doi.org/10.1007/s11655-009-0193-x

Xiao-mei Hu, Feng Liu, Chun-mei Zheng, et al. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. [J]. Chinese Journal of Integrative Medicine 15(3):193-197(2009)
Hu, Xm., Liu, F., Zheng, Cm. et al. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy., Chin. J. Integr. Med. 15, 193–197 (2009). https://doi.org/10.1007/s11655-009-0193-x DOI：

Xiao-mei Hu, Feng Liu, Chun-mei Zheng, et al. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. [J]. Chinese Journal of Integrative Medicine 15(3):193-197(2009) DOI： 10.1007/s11655-009-0193-x.

摘要

To observe the clinical efficacy of Chinese drugs combined with chemotherapy in the treatment of acute myeloid leukemia (AML) and to investigate the prognostic relevance of the main parameters in AML treated with integrative medicine. Forty AML patients hospitalized at the authors hospital were treated with Chinese drugs and chemotherapy. The routine examination

immunophenotype and karyotype analyses were carried out. The clinical efficacy was observed and the prognostic factors were analyzed. (1) Clinical efficacy: Twenty patients had complete remission (CR)

with the CR rate being 50.0%. Among these patients

the CR rate was 73.9% (17/23) in de novo AML and 17.6% (3/17) in secondary or refractory AML

respectively. The median disease free survival (DFS) was 6 months (2–32 months) and median overall survival (OS) was 7 months (1–36 months). (2) Analysis of prognostic factors: Aging (> 60 years) and hepatosplenomegaly or extramedullary leukemia did not affect the treatment outcome. Patients with lower white blood cell (WBC) counts (<4.0×109/L) had a significantly higher CR rate (P<0.01). Secondary or refractory AML was associated with a lower CR rate and shorter OS (P<0.01

P<0.05). Expression of CD34 was an adverse factor for obtaining CR (P<0.05) and survival in both DFS and OS (P<0.05

P<0.01). The expression of CD56 was significantly associated with a lower CR rate (P<0.05)

but did not affect DFS and OS. Twenty-three (57.5%) out of 40 cases had chromosomal abnormalities. The CR rate was decreased and both DFS and OS shortened stepwise from the cases with favorable cytogenetics to those with intermediate and unfavorable cytogenetics (P<0.01). The combined treatment of Chinese drugs with chemotherapy has a predominant effect in de novo AML. Secondary or refractory AML

expression of CD34 and CD56

and unfavorable cytogenetics were the main factors of poor prognosis in AML.

Abstract

with the CR rate being 50.0%. Among these patients

the CR rate was 73.9% (17/23) in de novo AML and 17.6% (3/17) in secondary or refractory AML

P<0.05). Expression of CD34 was an adverse factor for obtaining CR (P<0.05) and survival in both DFS and OS (P<0.05

P<0.01). The expression of CD56 was significantly associated with a lower CR rate (P<0.05)

expression of CD34 and CD56

and unfavorable cytogenetics were the main factors of poor prognosis in AML.

关键词

acute myeloid leukemiatreatmentIntegrative Medicineprognosisimmunophenotypecytogenetics

Keywords

acute myeloid leukemiatreatmentIntegrative Medicineprognosisimmunophenotypecytogenetics

references

Ma Y, Chen ZX. Analysis of current situation of treatment with Chinese drug combined with chemotheraly in acute leukemia. Chin J Integr Tradit West Med (Chin) 2002;12: 657–657.

Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004;28: 43–48.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison G, Rees J, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

Bennett JM, Catovsky D, Daniel MT, Daniel MT, Flandrin G, Galton DA, et al. Proposed revised criteria of the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Int Med 1985;103: 620.

National Leukemia Chemotherapy Conference. Criteria of curative effect on acute leukemia. Chin J Hematol (Chin) 1988;9:183.

Mitelman F. ISCN (1995): An international system for human cytogenetic nomenclature. Basel, S. Karger; 1995.

Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075–4083.

Shanghai Leukemia Cooperation: Observation of complete remission rate of initial treatment in acute leukemia in Shanghai region in 11 years. Chin J Hematol (Chin) 2000; 21:17–19.

Hu H, Xie CM, Xu F, Feng GP, Chen LF. Effects of supplementing qi and nourishing yin on immunological regulation and conservation of bone marrow in patients with acute leukemia received chemotherapy. J Sichuan Tradit Chin Med (Chin) 2007;25:50–52.

Chen SH, Chen ZX. Review of study on combined treatment of traditional Chinese medicine and Western medicine in acute leukemia. J Pract Tradit Chin Intern Med (Chin) 2002;16: 54–55.

Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001;15:1161–1164.

Suciu S, Mandelli F, De Witte T, Zittoun R, Gallo E, Labar B, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232–1240.

Hu XM, Wang HZ, Wang ZF, Zheng CM, Yang XH, Xu YG, et al. Trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia: a case report and literature review. J Clin Hematol (Chin) 2007; 20: 222–224.

Hu XM, Yang XH, Wang HZ, Liu C, Hu NP, Xu YG, et al. Deletions of chromosome 6q in two cases of acute myeloblastic leukemia and a review of the literature. J Leukemia Lymphoma (Chin) 2008;17:182–186.

FULL TEXT LINK

More>

Views

321

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Chinese medicine education and its challenges in the United States

Search of novel model for integrative medicine

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Syndrome pattern and its application in parallel randomized controlled trials

The Western model of integrative oncology — the contribution of Chinese medicine

Related Author

No data

Related Institution

Acupuncture & Oriental Medicine Program, National University of Health Sciences, Lombard

Interdisciplinary School of Health Sciences, University of Pune, Pune

Former Director, WHO Liaison Office New York

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Division of Clinical Medicine, School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰